| Literature DB >> 31899779 |
Beshir Bedru Nasir1, Alemseged Beyene Berha1, Meron Awraris Gebrewold2, Yared Mamushet Yifru2, Ephrem Engidawork1, Minyahil Alebachew Woldu1.
Abstract
OBJECTIVE: Epilepsy management especially in developing country is challenging. Seizures recurrence can be caused by both drug and non-drug related problems such as inadequate antiepileptic regimens, adverse drug reaction and poor adherence. Patient treatment satisfaction also affects the treatment out comes by improving medication adherence. This study aimed to assess drug therapy problems (DTPs) and treatment satisfaction among ambulatory epileptic patients at Tikur Anbessa Specialized Hospital.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31899779 PMCID: PMC6941812 DOI: 10.1371/journal.pone.0227359
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Socio demographic characteristics of epileptic patients attending at the neurology clinic of TASH, 2017.
| Male | 154 | 52.9 | |
| Female | 137 | 47.1 | |
| Adolescent (<18) | 39 | 13.4 | |
| Young adult (18–30) | 146 | 50.2 | |
| Adult (31–60) | 99 | 34.0 | |
| Elderly (>60) | 7 | 2.4 | |
| Single | 185 | 63.6 | |
| Married | 97 | 33.3 | |
| Divorced | 5 | 1.7 | |
| Widowed | 4 | 1.4 | |
| Addis Ababa | 238 | 81.8 | |
| Out of Addis Ababa | 53 | 18.2 | |
| No formal | 16 | 5.5 | |
| Primary | 88 | 30.2 | |
| Secondary | 105 | 36.1 | |
| Tertiary | 82 | 28.2 | |
| Unemployed | 112 | 38.5 | |
| Employed | 69 | 23.7 | |
| Private/ merchant | 49 | 16.8 | |
| Student | 50 | 17.2 | |
| Daily labourer | 2 | 0.7 | |
| Farmer | 6 | 2.1 | |
| Others | 3 | 1.0 | |
| Free | 140 | 48.1 | |
| Payment | 151 | 51.9 | |
* retired
Clinical characteristics of epileptic patients attending at the neurology clinic of TASH, 2017.
| Variables | Number (n) | Percentage (%) | ||
|---|---|---|---|---|
| 197 | 67.7 | |||
| GTCS | 193 | 66.3 | ||
| Myoclonic | 3 | 1.0 | ||
| Absence | 1 | 0.3 | ||
| 71 | 24.4 | |||
| Simple partial | 19 | 6.5 | ||
| Complex partial | 23 | 7.9 | ||
| Focal with secondary generalization | 29 | 10.0 | ||
| 23 | 7.9 | |||
| < 2 years | 49 | 16.8 | ||
| 2–5 years | 53 | 18.2 | ||
| 6–10 years | 69 | 23.7 | ||
| >10 years | 120 | 41.2 | ||
| < 1 year | 191 | 65.6 | ||
| 1–2 years | 46 | 15.8 | ||
| 2–5 years | 33 | 11.3 | ||
| >5 year | 21 | 7.7 | ||
| None | 102 | 35.1 | ||
| 1–5 | 120 | 41.2 | ||
| 6–10 | 32 | 11.0 | ||
| >10 | 37 | 12.7 | ||
| Co-morbid conditions | HIV | 20 | 6.9 | |
| CRVHD/CHF | 8 | 2.7 | ||
| Major depressive disorder | 10 | 3.4 | ||
| Migraine headache | 3 | 1.0 | ||
| Mental retardation | 5 | 1.7 | ||
| HTN | 12 | 4.1 | ||
| Stroke | 7 | 2.4 | ||
| Others | 14 | 4.8 | ||
“*Unclassified seizure”, a seizure which is diagnosed by the physician as “Epilepsy” or “seizure disorder”; GTCS, Generalized Tonic Clonic Seizure; HIV, human immune virus; CHF, Congestive Heart Failure; CRVHD, Chronic Rheumatic Valvular Heart Disease.
Pattern of medication use among epileptic patients attending at the neurology clinic of TASH, 2017.
| Variables | Number (N) | Percentage (%) | |
|---|---|---|---|
| One | 171 | 58.8 | |
| Two | 97 | 33.3 | |
| Three | 21 | 7.2 | |
| Four | 2 | 0.7 | |
| PHB | 93 | 32.0 | |
| PHT | 35 | 12.0 | |
| CBZ | 32 | 11.0 | |
| VPA | 17 | 5.8 | |
| LTG | 1 | 0.3 | |
| PHB+ PHT | 30 | 10.3 | |
| PHB+CBZ | 17 | 5.6 | |
| PHB+VPA | 15 | 5.2 | |
| PHB+LTG | 1 | 0.3 | |
| PHT+CBZ | 13 | 4.5 | |
| PHT+VPA | 9 | 3.1 | |
| CBZ+VPA | 7 | 2.4 | |
| PHB+PHT+CBZ | 4 | 1.4 | |
| CBZ+VPA+PHB | 4 | 1.4 | |
| PHB+PHT+VPA | 1 | 0.3 | |
| PHB+PHT+CLONA | 1 | 0.3 | |
| Others * | 11 | 3.8 | |
| 1 | 120 | 41.2 | |
| 2 | 97 | 33.3 | |
| >2 | 74 | 25.5 | |
Others *, different combination of the above AEDs including quadruple therapy; PHB, phenobarbital; PHT, phenytoin; CBZ, carbamazepine; VPA, Valproic acid; LTG, Lamotrigine; CLONA, Clonazepam.
Types of drug therapy problems identified from epileptic patients attending at the neurology clinic of TASH, 2017.
| 45 | 45 | 12.8 | ||
| Undesired effect | 144 | |||
| Contraindications | 2 | |||
| Inappropriate drug selection | 80 | |||
| Condition refractory to the drug | 18 | |||
| Untreated medical condition | 13 | |||
| Need synergistic/potentiating | 5 | |||
| Dose too low | 24 | |||
| Dose too high | 18 | |||
| No medical indication | 2 | |||
| 352 | 100 |
DTP: Drug Therapy Problems
Fig 1Type of drugs involved in drug interaction and their frequency.
Predictors of occurrence of drug therapy problems in epileptic patients attending at neurology clinic of TASH, 2017.
| Yes | No | |||||
|---|---|---|---|---|---|---|
| Male | 106(73.6) | 48(32.7) | 1.00 | 1.00 | ||
| Female | 38(23.6) | 99(67.3) | 1.18(0.711–1.957) | 1.19(.667–2.13) | 0.552 | |
| <18 | 33(16.1) | 6(7.0) | 1.00 | 1.00 | ||
| 18–30 | 104(50.7) | 42(48.8) | 0.450(0.176–1.153) | 0.371(0.129–1.068 | 0.066 | |
| 30–60 | 65(31.7) | 34(39.5) | 0.348(0.133–0.911) | 0.256(0.089–0.790 | 0.057 | |
| >60 | 3(1.5) | 4(4.7) | 0.136(0.024–0.770) | 0.135(0.017–1.081 | 0.059 | |
| 1 | 73(35.6) | 47(54.7) | 1.00 | 1.00 | ||
| 2 | 71(34.6) | 26(30.2) | 1.758(0.985–3.140) | 1.350(0.687–2.652) | 0.383 | |
| >2 | 61(29.8) | 13(15.1) | 3.273(1.594–6.719) | 3.810(1.409–10.30) | 0.008* | |
| No | 155(75.6) | 68(79.1) | 1.00 | 1.00 | ||
| Yes | 50(24.4) | 18(20.9) | 1.22(0.662–2.242) | 1.475(0.286–1.607) | 0.378 | |
COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval
Determinant factors associated with medication adherence among epileptic patients attending at neurology clinic of TASH, 2017.
| Non adherent | Adherent | |||||
|---|---|---|---|---|---|---|
| No formal | 4 (3.1) | 12 (7.4) | 1.00 | 1.00 | ||
| Primary | 40(31.0) | 48(29.6) | 2.500(0.748–8.358) | 2 .848(0. 824–9.839) | 0.098 | |
| Secondary | 46(35.7) | 59(36.4) | 2.339(0.708–7.730) | 3.266(0. 939–11.355) | 0.063 | |
| Tertiary | 39(30.2) | 43(2 6.6) | 2.721(0.810–9.141) | 5.177(1.412–18.584) | 0.013 | |
| < 1 | 98(76.0) | 93(57.4) | 1.00 | 1.00 | ||
| 1–2 | 14(10.9) | 32(19.8) | 0.415(0.208–0.827) | 0.359 (0.170–0.761) | 0.007* | |
| 2–5 | 11(8.5) | 22(13.6) | 0.474(0.218–1.032) | 0.455 (0.198–1.044) | 0.043* | |
| >5 | 6(4.6) | 15(9.2) | 0.380(0.141–1.020) | 0.368 (0.129–1.050) | 0.062 | |
| Paying | 55(42.6) | 96(59.3) | 1.00 | 1.00 | ||
| Free | 74(57.4) | 66(40.7) | 1.957(1.224–3.128) | 2.316(1.360–3.943) | 0.002* | |
| 1 | 45(34.9) | 75(46.3) | 1.00 | 1.00 | ||
| 2 | 45(34.9) | 52(32.1) | 1.442(0.837–2.485) | 1.295(0.731–2.298) | 0.098 | |
| >2 | 39(30.2) | 35(21.6) | 1.912(1.060–3.449) | 1.728(0.939–11.355) | 0.063 | |
| No | 60(46.5) | 87(53.7) | 1.00 | 1.00 | ||
| Yes | 69(53.5) | 75(46.3) | 1.334(0.839–2.121) | 1.273(0.784–2.080) | 0.327 | |
COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval
Patients’ treatment satisfaction among epileptic patients attending at neurology clinic of TASH, 2017.
| Undesirable side effects (0–100) | 87.1 ± 20.9 |
| Treatment effectiveness (0–100) | 64.7 ± 21.9 |
| Convenience of use (0–100) | 72.7 ± 17.0 |
| Impact on daily activities (0–100) | 62.0 ± 23.3 |
| Medical care (0–100) | 65.9 ± 20.7 |
| Global satisfaction (0–100) | 67.4 ± 17.5 |
| Total composite score (0–100) | 70.2 ± 12.5 |
SATMED-Q: Satisfaction with Medicines Questionnaire